SCHEMBL858136

SCHEMBL858136

Clc1cc2ncnc(Cl)c2cc1I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
ENPP1 P22413 3/20 0.42
CHEK1 O14757 1/20 0.39
DYRK1A Q13627 1/20 0.33
AXL P30530 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
SELE P16581 1/20 0.33
VCAM1 P19320 1/20 0.33
EGFR P00533 3/20 0.32
SRC P12931 3/20 0.32
RIPK2 O43353 1/20 0.32
NOD1 Q9Y239 1/20 0.32
MAP4K4 O95819 1/20 0.31
ALDH1A1 P00352 1/20 0.30
FBP1 P09467 1/20 0.30
RET P07949 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073470 0.83 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL2642415 0.81 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DENPP1
Hydrochloric Acid SCHEMBL3321635 0.79 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL856568 0.77 ENPP1 (0.63) ENPP1MKNK1EGFRSRCRIPK2
SCHEMBL30264799 0.77 ENPP1 (0.63) ENPP1MKNK1EGFRSRCRIPK2
SCHEMBL17030843 0.76 ENPP1 (0.46) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL855424 0.76 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL8646217 0.73 ENPP1 (0.44) PDE4APDE4BPDE4CPDE4DENPP1
Hydrochloric Acid SCHEMBL7501282 0.73 ENPP1 (0.35) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL23501083 0.73 ENPP1 (0.63) ENPP1MKNK1EGFRSRCRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE4A 1259/4885PDE4B 1027/4885PDE4C 1349/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE4A 1188/4885PDE4B 958/4885PDE4C 1209/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE4A 924/4885PDE4B 817/4885PDE4C 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.